Pure Global
NCT06124755

The Efficacy of Heparin-boned Viabahn Endoprosthesis and Paclitaxel-coated Balloons for Complex Femoropopliteal Lesions

Comparing the Efficacy of Heparin-boned Viabahn@ Endoprosthesis and Paclitaxel-coated Balloons for Endovascular Treatment of Complex Femoropopliteal Lesions
RenJi Hospital·ClinicalTrials.gov·device·Device trialNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Peripheral Arterial Disease
Drug/Device/Intervention
Viabahn endoprosthesis group
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
RenJi Hospital
Location
Shanghai, China
Timeline & enrollment
Phase
N/A
Start date
Dec 01, 2023
End date
Aug 31, 2027
Enrollment
60 participants
Primary outcome

Primary patency,Freedom from a composite of Major adverse events (MAEs)

Summary

The purpose of this study is to evaluate the effectiveness of the Viabahn endoprosthesis for
 treating long femoropopliteal lesions (stenosis ≥ 25cm, occlusion ≥ 15cm) or recurrent
 in-stent restenosis compared to drug-coated balloons (DCB) with or without a bailout bare
 nitinol stent.

ICD-10 classifications
Peripheral vascular disease, unspecifiedOther peripheral vascular diseasesOther specified peripheral vascular diseasesPeripheral angiopathy in diseases classified elsewhereOther congenital malformations of peripheral vascular system
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06124755
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06124755 through Pure Global AI's free database. This phase not specified trial is sponsored by RenJi Hospital and is currently Not yet recruiting. The study focuses on Peripheral Arterial Disease. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.